Molecular simulation study of CYP2B6 polymorphism with and without psoralen

被引:0
|
作者
Lu, Nan [1 ,2 ]
Meng, Fancui [3 ]
Xu, Weiren [3 ]
Tang, Lida [3 ]
Xu, Youjun [1 ,2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Shenyang, Liaoning, Peoples R China
[3] Tianjin Inst Pharmaceut Res, Tianjin Key Lab Mol Design & Drug Discovery, Tianjin, Peoples R China
关键词
CYP2B6; psoralen; molecular dynamics; molecular docking; mechanism-based inactivation; MECHANISM-BASED INACTIVATION; SINGLE NUCLEOTIDE POLYMORPHISM; CYTOCHROMES P450; FUNCTIONAL-CHARACTERIZATION; ALLELIC VARIANTS; STRUCTURAL BASIS; IN-SILICO; ACTIVATION; INHIBITION; EXPRESSION;
D O I
10.1080/08927022.2018.1513646
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
CYP2B6 is a polymorphic enzyme with a large number of variants which may lead to functional changes in enzyme activity and substrate selectivity. In this study, CYP2B6 and its three variants with and without psoralen, a mechanism-based inactivator, were investigated using molecular simulation method. The obtained docking orientation of psoralen was in agreement with previously identified site of metabolism. Stability analysis showed that the three variants displayed more flexibility than CYP2B6.1, and CYP2B6.34 was the most flexible one without psoralen binding. However, in the presence of psoralen, CYP2B6.34 became more rigidity. Tunnel analysis indicates that the bottleneck change of tunnels may be correlated to the increased or decreased activity of variants. Binding free energy analysis shows that van der Waals interaction dominates the binding of psoralen. CYP2B6.34 has the highest affinity to psoralen with lowest binding free energy. Ile114, Phe115 and heme contribute largely to the binding of psoralen with CYP2B6.6, while Phe206 and Leu363 play important roles for CYP2B6.1 and CYP2B6.4. These computational observations suggest that the increased activity of CYP2B6.4 and reduced activity of CYP2B6.6 may be due to changes in regional structures.
引用
收藏
页码:1402 / 1410
页数:9
相关论文
共 50 条
  • [1] Psoralen, a mechanism-based inactivator of CYP2B6
    Ji, Lin
    Lu, Dan
    Cao, Jiaojiao
    Zheng, Liwei
    Peng, Ying
    Zheng, Jiang
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2015, 240 : 346 - 352
  • [2] Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
    D'Avolio, Antonio
    De Francia, Silvia
    Basile, Vittoria
    Cusato, Jessica
    De Martino, Francesca
    Pirro, Elisa
    Piccione, Francesca
    Ardito, Arianna
    Zaggia, Barbara
    Volante, Marco
    Di Perri, Giovanni
    Terzolo, Massimo
    [J]. PHARMACOGENETICS AND GENOMICS, 2013, 23 (06): : 293 - 300
  • [3] Molecular characterization of CYP2B6 substrates
    Ekins, Sean
    Iyer, Manisha
    Krasowski, Matthew D.
    Kharasch, Evan D.
    [J]. CURRENT DRUG METABOLISM, 2008, 9 (05) : 363 - 373
  • [4] Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking
    Christine Bathelt
    Rolf D. Schmid
    Jürgen Pleiss
    [J]. Molecular modeling annual , 2002, 8 : 327 - 335
  • [5] Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking
    Bathelt, C
    Schmid, RD
    Pleiss, J
    [J]. JOURNAL OF MOLECULAR MODELING, 2002, 8 (11) : 327 - 335
  • [6] CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!
    Cook-Sather, Scott D.
    Adamson, Peter C.
    Li, Jin
    Hakonarson, Hakon
    [J]. ANESTHESIOLOGY, 2016, 125 (06) : 1085 - 1087
  • [7] Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance
    Nolan, D
    Phillips, E
    Mallal, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) : 408 - 410
  • [8] Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Desta, Zeruesenay
    Saussele, Tanja
    Ward, Bryan
    Blievernicht, Julia
    Li, Lang
    Klein, Kathrin
    Flockhart, DavidA
    Zanger, Ulrich M.
    [J]. PHARMACOGENOMICS, 2007, 8 (06) : 547 - 558
  • [9] ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS
    Somogyi, A. A.
    Coller, J. K.
    Foster, D. B. F.
    Li, Y.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 32 - 32
  • [10] Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese
    To, Kin Wang
    Liu, Shui Teng
    Cheung, Siu Wai
    Chan, D. Pui Chung
    Chan, R. Chiu Yeung
    Lee, Shui Shan
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (04) : 527 - 530